Tags

Type your tag names separated by a space and hit enter

Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction.

Abstract

The art of ovarian stimulation for IVF/ICSI treatment using exogenous FSH should be balanced against the relative contribution of other steps of the ART process such as the IVF-lab-phase and the Embryo-Transfer. The aim of ovarian stimulation is to obtain a certain number of oocytes, that will enable the best probability of achieving a live birth. It has been suggested that more oocytes will create a better prospect for pregnancy, but studies on the question whether the retrieval of a few oocytes less or more will make the difference are not clearly supportive for this mantra. Personalization strategies have been the subject of many studies over the past 20 years. Creating the optimal response in a patient in terms of live birth prognosis as well as OHSS risks may be based on information from the Ovarian Reserve testing using the Antral Follicle Count or Anti-Mullerian Hormone, the patient's bodyweight, the ovarian response in a previous cycle, and the dosage level of FSH. Taken together, steering the ovarian response into a supposed optimal range may appear difficult as the interrelation for each of these factors with the egg number is weak. Using OR testing for choosing FSH dosage, compared to a standard normal dosage of 150 IU, has been studied in several trials. Dosage individualization, in general, does not appear to improve the prospects for live birth, but the reduction in OHSS risk may be substantial. This implies that the use of high dosages of FSH in predicted LOW responders lacks any cost-benefit for the patient and may be abandoned, while in predicted HIGH responders, reduction of the usual dosage level of 150 IU may create better safety, provided that in case of an unexpected LOW response cancelation of the cycle is refrained from. In view of recent developments in using GnRH agonist triggering of final oocyte maturation, the trend could be that with the Antagonist co-medication system and a standard dosage of 150 IU of FSH, prior ovarian reserve testing may become futile, as safety can be managed well in actual HIGH responders by replacing the high dose hCG trigger.

Authors+Show Affiliations

University Medical Center Utrecht, Utrecht, Netherlands.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31080437

Citation

Broekmans, Frank J.. "Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction." Frontiers in Endocrinology, vol. 10, 2019, p. 181.
Broekmans FJ. Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction. Front Endocrinol (Lausanne). 2019;10:181.
Broekmans, F. J. (2019). Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction. Frontiers in Endocrinology, 10, 181. https://doi.org/10.3389/fendo.2019.00181
Broekmans FJ. Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction. Front Endocrinol (Lausanne). 2019;10:181. PubMed PMID: 31080437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction. A1 - Broekmans,Frank J, Y1 - 2019/04/26/ PY - 2018/11/01/received PY - 2019/03/04/accepted PY - 2019/5/14/entrez PY - 2019/5/14/pubmed PY - 2019/5/14/medline KW - FSH KW - OHSS KW - dosage individualization KW - live birth KW - ovarian reserve testing KW - ovarian response KW - ovarian stimulation KW - safety SP - 181 EP - 181 JF - Frontiers in endocrinology JO - Front Endocrinol (Lausanne) VL - 10 N2 - The art of ovarian stimulation for IVF/ICSI treatment using exogenous FSH should be balanced against the relative contribution of other steps of the ART process such as the IVF-lab-phase and the Embryo-Transfer. The aim of ovarian stimulation is to obtain a certain number of oocytes, that will enable the best probability of achieving a live birth. It has been suggested that more oocytes will create a better prospect for pregnancy, but studies on the question whether the retrieval of a few oocytes less or more will make the difference are not clearly supportive for this mantra. Personalization strategies have been the subject of many studies over the past 20 years. Creating the optimal response in a patient in terms of live birth prognosis as well as OHSS risks may be based on information from the Ovarian Reserve testing using the Antral Follicle Count or Anti-Mullerian Hormone, the patient's bodyweight, the ovarian response in a previous cycle, and the dosage level of FSH. Taken together, steering the ovarian response into a supposed optimal range may appear difficult as the interrelation for each of these factors with the egg number is weak. Using OR testing for choosing FSH dosage, compared to a standard normal dosage of 150 IU, has been studied in several trials. Dosage individualization, in general, does not appear to improve the prospects for live birth, but the reduction in OHSS risk may be substantial. This implies that the use of high dosages of FSH in predicted LOW responders lacks any cost-benefit for the patient and may be abandoned, while in predicted HIGH responders, reduction of the usual dosage level of 150 IU may create better safety, provided that in case of an unexpected LOW response cancelation of the cycle is refrained from. In view of recent developments in using GnRH agonist triggering of final oocyte maturation, the trend could be that with the Antagonist co-medication system and a standard dosage of 150 IU of FSH, prior ovarian reserve testing may become futile, as safety can be managed well in actual HIGH responders by replacing the high dose hCG trigger. SN - 1664-2392 UR - https://www.unboundmedicine.com/medline/citation/31080437/Individualization_of_FSH_Doses_in_Assisted_Reproduction:_Facts_and_Fiction L2 - https://doi.org/10.3389/fendo.2019.00181 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.